2022
Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model
Hinahara J, Weinzimer SA, Bromley ER, Goss TF, Kendall DM, Hammer M. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model. Journal Of Managed Care & Specialty Pharmacy 2022, 28: 10.18553/jmcp.2022.28.4.461. PMID: 35332789, PMCID: PMC10373001, DOI: 10.18553/jmcp.2022.28.4.461.Peer-Reviewed Original ResearchConceptsBudget impact modelHealth care resource utilizationSevere hypoglycemiaSH eventsGlucagon treatmentNasal glucagonUS commercial health planLower total health care costsSuccessful administrationTotal direct medical costsTotal health care costsPlasma glucose recoveryEmergency department visitsSevere hypoglycemic eventsInitial treatment successDirect medical costsCommercial health plansType 2 diabetesHealth care costsHealth economic modelEmergency medical servicesNative glucagonGlucagon analogsInjectable glucagonPrompt administration
2009
Blunted Counterregulatory Hormone Responses to Hypoglycemia in Young Children and Adolescents With Well-Controlled Type 1 Diabetes
Tsalikian E, Tamborlane W, Xing D, Becker D, Mauras N, Fiallo-Scharer R, Buckingham B, Weinzimer S, Steffes M, Singh R, Beck R, Ruedy K, Kollman C. Blunted Counterregulatory Hormone Responses to Hypoglycemia in Young Children and Adolescents With Well-Controlled Type 1 Diabetes. Diabetes Care 2009, 32: 1954-1959. PMID: 19675205, PMCID: PMC2768200, DOI: 10.2337/dc08-2298.Peer-Reviewed Original ResearchConceptsType 1 diabetesPlasma glucose concentrationEpinephrine responsePlasma glucoseYoung childrenInsulin pump-treated patientsHypoglycemia-associated autonomic failurePump-treated patientsLower plasma glucose concentrationsIntensive insulin therapySymptoms of hypoglycemiaInsulin infusion protocolCounterregulatory hormone concentrationsGlucose concentrationAbsence of signsClosed-loop insulin delivery systemsContinuous glucose monitoringAcute complicationsAutonomic failureCounterregulatory hormonesSympathoadrenal responseInsulin therapyPatient ageNondiabetic adolescentsSymptom scores